News
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...
Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...
Gilead has been a leader in HIV innovation for decades. Now, we're proud to share that one of our researchers, Moupali Das, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results